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ATOVAQ UONE VS. DAP SONE F OR P NE UM OCYST IS CA R INII PNEUMONIA IN PATIENTS WITH H IV INFEC TION

ATOVAQUONE COMPARED WITH DAPSONE FOR THE PREVENTION OF
PNEUMOCYSTIS CARINII PNEUMONIA IN PATIENTS WITH HIV INFECTION
WHO CANNOT TOLERATE TRIMETHOPRIM, SULFONAMIDES, OR BOTH
WAFAA M. EL-SADR, M.D., M.P.H., ROBERT L. MURPHY, M.D., TERESA MCCABE YURIK, M.S.,
ROBERTA LUSKIN-HAWK, M.D., TONY W. CHEUNG, M.D., HENRY H. BALFOUR, JR., M.D., ROBERT ENG, M.D.,
THOMAS M. HOOTON, M.D., THOMAS M. KERKERING, M.D., MALTE SCHUTZ, M.D.,
CHARLES VAN DER HORST, M.D., AND RICHARD HAFNER, M.D.,
FOR THE COMMUNITY PROGRAM FOR CLINICAL RESEARCH ON AIDS AND THE AIDS CLINICAL TRIALS GROUP*

ABSTRACT
Background Although trimethoprim–sulfamethoxazole is the drug of choice for the prevention of
Pneumocystis carinii pneumonia, many patients cannot tolerate it and must switch to an alternative agent.
Methods We conducted a multicenter, open-label,
randomized trial comparing daily atovaquone (1500mg suspension) with daily dapsone (100 mg) for the
prevention of P. carinii pneumonia among patients
infected with the human immunodeficiency virus
who could not tolerate trimethoprim–sulfamethoxazole. The median follow-up period was 27 months.
Results Of 1057 patients enrolled, 298 had a history
of P. carinii pneumonia. P. carinii pneumonia developed in 122 of 536 patients assigned to atovaquone
(15.7 cases per 100 person-years), as compared with
135 of 521 in the dapsone group (18.4 cases per 100
person-years; relative risk for atovaquone vs. dapsone, 0.85; 95 percent confidence interval, 0.67 to
1.09; P=0.20). The relative risk of death was 1.07 (95
percent confidence interval, 0.89 to 1.30; P=0.45),
and the relative risk of discontinuation of the assigned medication because of adverse events was
0.94 (95 percent confidence interval, 0.74 to 1.19;
P=0.59). Among the 546 patients who were receiving
dapsone at base line, the relative risk of discontinuation because of adverse events was 3.78 for atovaquone as compared with dapsone (95 percent confidence interval, 2.37 to 6.01; P<0.001); among those
not receiving dapsone at base line, it was 0.42 (95
percent confidence interval, 0.30 to 0.58; P<0.001).
Conclusions Among patients who cannot tolerate
trimethoprim–sulfamethoxazole, atovaquone and dapsone are similarly effective for the prevention of
P. carinii pneumonia. Our results support the continuation of dapsone prophylaxis among patients who are
already receiving it. However, among those not receiving dapsone, atovaquone is better tolerated and may
be the preferred choice for prophylaxis against
P. carinii pneumonia. (N Engl J Med 1998;339:1889-95.)
©1998, Massachusetts Medical Society.

T

HE prevention of Pneumocystis carinii pneumonia has had a substantial influence on
the course of human immunodeficiency
virus (HIV) disease.1,2 Although trimethoprim–sulfamethoxazole is the treatment of choice for
prophylaxis against P. carinii pneumonia, intolerance often limits its use and makes it necessary to use
alternative regimens.3 Dapsone, alone or in combination with pyrimethamine, is a commonly recommended prophylactic regimen for P. carinii pneumonia in
patients who cannot tolerate trimethoprim–sulfamethoxazole.4 Dapsone plus pyrimethamine has
been shown to be superior to aerosolized pentamidine for the prevention of toxoplasmosis.5 However,
dapsone has limitations: it is less effective than trimethoprim–sulfamethoxazole for the prevention of
P. carinii pneumonia and is associated with a high
rate of intolerance.6,7
Atovaquone, an agent with antipneumocystis activity in studies in animals,8 has been shown to be effective and reasonably well tolerated for the treatment of mild-to-moderate P. carinii pneumonia in
HIV-infected patients.9 However, there have been no
large studies of the efficacy and tolerability of atovaquone for the prevention of P. carinii pneumonia.
The Community Program for Clinical Research
on AIDS (CPCRA) and the AIDS Clinical Trials
Group (ACTG) initiated a randomized study comparing atovaquone suspension with dapsone for the prevention of P. carinii pneumonia among HIV-infected
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Minneapolis; Saint Joseph’s Medical Center, Chicago (R.L.-H.); Mount
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Hospital, East Orange, N.J. (R.E.); the University of Washington, Seattle
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patients who could not tolerate trimethoprim, sulfonamides, or both.
METHODS
Study Population
HIV-infected patients 13 years of age or older were eligible for
the study if they had a history of P. carinii pneumonia (this group
received secondary prophylaxis), or if they had no history of
P. carinii pneumonia and had a CD4+ lymphocyte count no
higher than 200 per cubic millimeter or no more than 15 percent
of the total lymphocyte count (this group received primary prophylaxis). Patients were also required to have a history of a treatmentlimiting reaction to sulfonamides or trimethoprim, no history of
intolerance of dapsone or atovaquone, and adequate glucose-6phosphate dehydrogenase levels.
Study Design
The study was a randomized, open-label clinical trial comparing
the efficacy of atovaquone (Mepron, Glaxo Wellcome, Research
Triangle Park, N.C.; given as a 1500-mg suspension once daily) and
dapsone (Jacobus Pharmaceuticals, Princeton, N.J.; 100-mg tablets,
given once daily) in delaying or preventing the onset of confirmed
or probable P. carinii pneumonia. Patients randomly assigned to
receive dapsone who had CD4+ cell counts under 100 per cubic
millimeter and positive results on serologic tests for toxoplasma
were encouraged to take pyrimethamine (50 mg) and leucovorin
(15 mg) each week. Patients in whom P. carinii pneumonia developed or who had an adverse event necessitating the discontinuation
of the assigned treatment could be switched to the other study
treatment. Patients were randomly assigned to treatment in a 1:1
ratio according to a permuted-block design, with stratification according to the clinical center, history with respect to P. carinii
pneumonia, and serologic status with respect to toxoplasma.
The sample size and duration of follow-up (18 months from
the time the last patient was enrolled) were calculated to provide
the study with 80 percent power to detect a 50 percent decrease
in the risk of P. carinii pneumonia among the patients assigned
to atovaquone, as compared with those assigned to dapsone, at a
0.05 level of significance (in a two-sided test). It was assumed
that P. carinii pneumonia would develop in 20 percent of the patients receiving dapsone for primary prophylaxis and in 40 percent
of those receiving dapsone for secondary prophylaxis. It was also
assumed that 80 percent of the participants would receive primary
prophylaxis, and 20 percent secondary prophylaxis. Overall mortality at two years in the absence of P. carinii pneumonia was
assumed to be 20 percent and 40 percent for those receiving primary and secondary prophylaxis, respectively. The study was approved by each medical center’s institutional review board, and
the participants were required to provide written informed consent in order to participate.
End Points and Follow-up
The primary end point was the development of confirmed or
probable P. carinii pneumonia. Confirmation required histologic
or cytologic identification of P. carinii in bronchoalveolar-lavage,
lung-biopsy, or sputum specimens. A probable diagnosis was based
on a history of either exertional dyspnea or nonproductive cough;
evidence of diffuse bilateral pulmonary disease on either a chest
roentgenogram or a gallium scan, or abnormal arterial-blood gases; and the absence of another condition that could account for
the findings. The end points were reviewed by a clinical-events
committee whose members were unaware of the patients’ treatment assignments. The secondary end points were intolerance of
the study drug necessitating the permanent discontinuation of
the drug, death, the combined end point of P. carinii pneumonia
or death, and confirmed or probable toxoplasmosis. A four-point
scale was used to grade the severity of adverse events (grade 4
events were severe and potentially life-threatening).

1890 ·

Statistical Analysis
Investigators were unaware of all interim results, which were reviewed by an independent data and safety monitoring board. The
treatment groups were compared by means of Kaplan–Meier
event–time curves, log-rank tests, and proportional-hazards regression models.10 Primary analyses were performed according to the
intention-to-treat principle and were stratified according to the
trial group (CPCRA or ACTG), history with respect to P. carinii
pneumonia, and results of serologic tests for toxoplasma. Relative
risks (atovaquone vs. dapsone) are given with 95 percent confidence intervals. Secondary analyses were also performed. In an
“on-treatment” analysis, follow-up data were censored 30 days after
the assigned study treatment was discontinued. In a second analysis, which was conducted because of the low rate of P. carinii
pneumonia during the later follow-up period, follow-up data
were censored when therapy was initiated with protease inhibitors.
The proportional-hazards model was used to estimate the risk of
P. carinii pneumonia for patients who discontinued the study
treatment as compared with those who did not. In this analysis,
a single time-varying indicator of discontinuation of all study
treatment was included in the regression model. All P values are
two-tailed; all median times reported account for censoring.

RESULTS
Characteristics of the Patients

Between October 4, 1994, and May 5, 1995, 1057
patients were enrolled in the study, 194 from 11
CPCRA units and 863 from 37 ACTG units. The
two treatment groups were well balanced with regard to base-line characteristics (Table 1). Overall,

TABLE 1. BASE-LINE CHARACTERISTICS ACCORDING
TREATMENT GROUP.*

CHARACTERISTIC

TO

ATOVAQUONE
(N=536)

DAPSONE
(N=521)

38.4
11.2

37.8
13.6

20.5
11.8
65.7
2.1
18.6
57.5
74.4
53.2
17.9
2.6

23.2
12.5
62.8
1.5
16.9
59.5
72.4
50.1
19.2
2.5

82.5
6.9
3.7
6.9
49.6
28.7
16.2
87.7
55

78.7
8.8
5.8
6.7
47.6
27.6
15.9
87.7
65

Mean age (yr)
Female sex (%)
Race or ethnic group (%)
Black
Hispanic
White
Other
History of injection-drug use (%)
Antiretroviral therapy (%)
PCP prophylaxis at randomization (%)
Dapsone
Pentamidine
Other
Adverse reaction to TMP–SMX (%)
Hypersensitivity
Gastrointestinal symptoms
Hematologic abnormalities
Other
Prior diagnosis of AIDS (%)
Prior PCP (%)
Positive toxoplasma titer (%)
Mean Karnofsky score
Median CD4+ count (cells/mm3)

*PCP denotes Pneumocystis carinii pneumonia, TMP–SMX trimethoprim–sulfamethoxazole, and AIDS the acquired immunodeficiency syndrome.
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21.9 percent were black, 12.1 percent were Hispanic,
17.7 percent were injection-drug users, and 12.4 percent were female. A history of P. carinii pneumonia
was reported by 298 patients (28.2 percent). Overall, the median base-line CD4+ lymphocyte count
was 60 per cubic millimeter, and 16.1 percent of the
patients had positive serologic tests for toxoplasma.
At base line, 73.4 percent of the patients were receiving prophylaxis against P. carinii pneumonia (51.7
percent were receiving dapsone, 18.5 percent pentamidine, and 3.2 percent other treatments or a combination of treatments), and 58.6 percent of the patients were receiving antiretroviral treatment (46.9
percent were receiving nucleoside monotherapy, and
11.7 percent nucleoside combination therapy). At the
12-month follow-up visit, 70.5 percent of the patients were receiving antiretroviral therapy, with 31.3
percent receiving combination nucleoside therapy. At
the 24-month follow-up visit, 93.0 percent of the
patients were receiving antiretroviral therapy, with
17.2 percent taking combination nucleoside regimens
and 71.9 percent (71.7 percent of the atovaquone
group and 72.0 percent of the dapsone group) using
regimens containing protease inhibitors.
Duration of Follow-up and Study Treatment

At the end of the study, on April 11, 1997, the median follow-up was 27 months for each treatment
group. At this time, the status with respect to P. carinii pneumonia was unknown for 5.0 percent of patients assigned to atovaquone and 7.1 percent of those
assigned to dapsone. The vital status of 5.0 percent of
the patients in the atovaquone group and 6.7 percent
of those in the dapsone group was unknown.

TABLE 2. SUMMARY
EVENT AND PCP
PROPHYLAXIS GROUP†

OF

P. carinii Pneumonia

A total of 257 patients had at least one episode of
confirmed or probable P. carinii pneumonia: 122 in
the atovaquone group (15.7 cases per 100 personyears) and 135 in the dapsone group (18.4 per 100
person-years; relative risk for atovaquone vs. dapsone, 0.85; 95 percent confidence interval, 0.67 to
1.09; P=0.20) (Table 2). The cumulative percentages
of patients who had had at least one episode of confirmed or probable P. carinii pneumonia after 6, 12,
and 24 months were 8.9 percent, 19.5 percent, and
26.5 percent for patients assigned to atovaquone and
13.5 percent, 21.3 percent, and 29.5 percent for patients assigned to dapsone (Fig. 1). In both treatment groups, the risk of P. carinii pneumonia declined after the first year of follow-up. The relative
risk of P. carinii pneumonia in the two groups did
not differ significantly when data were censored at
the time of initiation of therapy with protease inhibitors (relative risk, 0.84; P=0.19).
Confirmed cases of P. carinii pneumonia developed

EVENTS ACCORDING

ATOVAQUONE
(N=536)
NO. OF

PCP‡
All patients
Primary
Secondary
Death
All patients
Primary
Secondary

Of the 617 patients who were alive at the close of
the study, 289 (47 percent) were receiving study-supplied dapsone or atovaquone: 214 (35 percent) were
still taking the originally assigned drug, and 75 (12
percent) had been switched to the alternative treatment. The median time during which patients took
the assigned drug was 7.2 months for atovaquone
and 7.4 months for dapsone. The median time during
which they took either the assigned drug or the alternative was 10.8 months for those assigned to
atovaquone and 11.9 months for those assigned to
dapsone (P=0.22).

TO

TREATMENT GROUP.*

DAPSONE
(N=521)

RR (95% CI)

P
VALUE

NO. OF

PATIENTS

EVENT

PATIENTS

EVENT

WITH EVENT

RATE

WITH EVENT

RATE

122
67
55

15.7
11.3
29.7

135
81
54

18.4
14.1
33.9

0.85 (0.67–1.09)
0.81 (0.58–1.12)
0.92 (0.62–1.34)

0.20
0.20
0.65

232
150
82

26.2
23.2
34.2

208
121
87

24.1
18.6
41.2

1.07 (0.89–1.30)
1.25 (0.98–1.59)
0.85 (0.62–1.14)

0.45
0.07
0.28

*Rates are per 100 person-years. Relative risks for atovaquone versus dapsone and associated P values
are derived from proportional-hazards regression models, with stratification factors corresponding to
trial group (ACTG or CPCRA) and presence or absence of a history of P. carinii pneumonia at base
line. PCP denotes P. carinii pneumonia, RR relative risk, and CI confidence interval.
†Patients with no history of P. carinii pneumonia received primary prophylaxis, and those with a
history of P. carinii pneumonia received secondary prophylaxis.
‡A PCP event was defined as the first occurrence of confirmed or probable P. carinii pneumonia
after randomization.
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0

quone (36.1 events per 100 person-years) and 274
assigned to dapsone (37.0 per 100 person-years; relative risk, 0.98; 95 percent confidence interval, 0.83
to 1.16; P=0.80).

Atovaquone
Dapsone

Subgroup Analyses

0

6

12

18

24

30

Months after Randomization
NO. AT RISK
AtovaquoneI 536I
Dapsone
521

343I
324

240I
202

Figure 1. Kaplan–Meier Estimates of the Percentage of Patients
Who Remained Free of P. carinii Pneumonia, According to
Treatment Group.

in 93 patients assigned to atovaquone (11.6 cases per
100 person-years) and 109 patients assigned to dapsone (14.4 per 100 person-years; relative risk, 0.79; 95
percent confidence interval, 0.60 to 1.04; P=0.09).
Among patients who were receiving their originally
assigned treatment or who had discontinued or
switched treatment not more than 30 days previously
(on-treatment analysis), P. carinii pneumonia developed in 83 patients assigned to atovaquone (17.0
cases per 100 person-years) and in 101 patients assigned to dapsone (20.8 per 100 person-years; relative risk, 0.80; 95 percent confidence interval, 0.59
to 1.07; P=0.13). Patients who discontinued all study
treatment had a 37 percent lower rate of P. carinii
pneumonia than those who continued to receive the
study-supplied medication (P=0.02).
Toxoplasmosis

Confirmed or probable toxoplasmosis developed
in 7 of the 170 patients who were seropositive for
toxoplasma at base line (4 assigned to atovaquone and
3 assigned to dapsone) (relative risk, 1.18; 95 percent confidence interval, 0.26 to 5.30; P=0.83).
Mortality

A total of 440 patients died during the study.
Death rates were similar for the two treatment
groups; there were 232 deaths (26.2 per 100 personyears) among patients assigned to atovaquone and
208 (24.1 per 100 person-years) among those assigned to dapsone (relative risk, 1.07; 95 percent
confidence interval, 0.89 to 1.30; P=0.45) (Table 2).
P. carinii Pneumonia or Death

A total of 555 patients had confirmed or probable
P. carinii pneumonia or died: 281 assigned to atova1892 ·

Among patients receiving primary prophylaxis, the
relative risk of P. carinii pneumonia for atovaquone
versus dapsone was 0.81 (P=0.20), and the relative
risk of death was 1.25 (P=0.07). Among patients
receiving secondary prophylaxis, the relative risk was
0.92 (P=0.65) for P. carinii pneumonia and 0.85
(P=0.28) for death (Table 2). The relative risk of
death was significantly different in the subgroup of
patients receiving primary prophylaxis and the subgroup receiving secondary prophylaxis (P=0.03). The
relative risk of P. carinii pneumonia in the atovaquone group versus the dapsone group was 0.99
among patients already receiving dapsone at base
line (P=0.95) and 0.68 among those not receiving
dapsone at base line (P=0.05).
Adverse Events and Discontinuation of Study Drugs

Among the patients assigned to atovaquone, 436
(81 percent) discontinued the study medication, including 146 who were switched to dapsone. The
most common reasons for discontinuation were intolerance (25 percent), the patient’s request (18 percent), development of P. carinii pneumonia (16 percent), and death (14 percent). Among the patients
assigned to dapsone, 407 (78 percent) discontinued
the medication, including 149 who were switched to
atovaquone. For these patients, the most common
reasons for discontinuation were intolerance (26 percent), development of P. carinii pneumonia (17 percent), death (17 percent), and the patient’s request
(9 percent).
The overall rates of discontinuation because of an
inability to tolerate the study drug did not differ significantly between treatment groups (relative risk for
atovaquone vs. dapsone, 0.94; P=0.59) (Table 3).
Among patients who discontinued atovaquone because of intolerance, 74 percent had grade 1 or 2 adverse events, and 25 percent had grade 3 or 4 adverse
events. In the dapsone group, 63 percent of the patients who discontinued the drug because of intolerance had grade 1 or 2 adverse events, and 36 percent
had grade 3 or 4 adverse events. (Grades were not
available for three patients.) The specific adverse
events varied according to the treatment group. As
compared with patients assigned to dapsone, more
patients assigned to atovaquone discontinued the drug
because of upper gastrointestinal symptoms (relative
risk, 6.79; P<0.001) or diarrhea (relative risk, 16.6;
P=0.01). However, fewer patients assigned to atovaquone discontinued the study drug because of hypersensitivity reactions, such as rash, fever, allergic reaction, pruritus, and dermatitis (relative risk, 0.50;
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TABLE 3. DISCONTINUATION
REASON FOR
DISCONTINUATION

OF

ORIGINALLY ASSIGNED STUDY DRUG ACCORDING

ALL PATIENTS (N=1057)

BASE-LINE DAPSONE (N=546)

ATOVA-

Adverse event

TO

NO BASE-LINE DAPSONE (N=511)

ATOVA-

QUONE

DAPSONE

(N=536)

(N=521)

RR
(95% CI)

BASE-LINE DAPSONE USE.*

ATOVA-

P

QUONE

DAPSONE

VALUE

(N=285)

(N=261)

RR
(95% CI)

P

QUONE

DAPSONE

VALUE

(N=251)

(N=260)

no. of events (rate)

no. of events (rate)

no. of events (rate)

133 (28.1) 137 (28.6)

80 (32.1) 24 (8.4)

53 (23.6) 113 (58.4)

Hyper46 (9.7)
sensitivity
Anemia
0 (0.0)
Upper gastro- 34 (7.2)
intestinal
symptoms
Diarrhea
16 (3.4)

0.94
0.59
(0.74–1.19)
86 (18.0)
0.50
<0.001
(0.35–0.72)
10 (2.1)
—
0.001
5 (1.0)
6.79
<0.001
(2.65–17.4)

3.78
<0.001
(2.37–6.01)
23 (9.2) 11 (3.9)
2.28
0.03
(1.11–4.70)
0 (0.0) 5 (1.8)
—
0.02
23 (9.2) 0 (0.0)
—
<0.001

1 (0.2)

16.6
0.01
10 (4.0) 0 (0.0)
—
0.002
(2.20–125)
Patient’s request 95 (20.1) 45 (9.4)
2.06
<0.001 50 (20.1) 26 (9.1)
2.13
0.002
(1.44–2.94)
(1.32–3.43)
Adverse event 228 (48.1) 182 (38.0)
0.05 130 (52.2) 50 (17.5)
2.90
<0.001
1.21
or patient’s
(1.00–1.48)
(2.09–4.04)
request

23 (10.2)
0 (0.0)
11 (4.9)
6 (2.7)

RR
(95% CI)

P
VALUE

0.42
<0.001
(0.30–0.58)
75 (38.7)
0.29
<0.001
(0.18–0.46)
5 (2.6)
—
0.06
5 (2.6)
1.87
0.25
(0.65–5.40)
1 (0.5)

5.76
(0.69–48.3)
45 (20.1) 19 (9.8)
2.09
(1.21–3.59)
98 (43.7) 132 (68.2)
0.66
(0.51–0.86)

0.11
0.01
0.002

P<0.001), or anemia (0 vs. 2.1 per 100 personyears; P=0.001).
Of the patients receiving dapsone at base line,
those who were assigned to atovaquone were significantly more likely than those assigned to dapsone to
discontinue the assigned treatment because of adverse events (relative risk, 3.78; 95 percent confidence
interval, 2.37 to 6.01; P<0.001) (Table 3). The opposite was true for patients who were not taking
dapsone at base line (relative risk, 0.42; 95 percent
confidence interval, 0.30 to 0.58; P<0.001). The
difference in relative risks was largely the result of
different rates of discontinuation among patients assigned to dapsone. There was a sixfold difference in
the rate of discontinuation of study-assigned dapsone
because of adverse events between those taking and
those not taking dapsone at base line (8.4 and 58.4
per 100 person-years, respectively). Table 3 shows
the rates of discontinuation due to the most commonly reported adverse events, according to dapsone use at base line.
A significantly larger number of patients assigned
to atovaquone requested that the study medication
be discontinued in the absence of an adverse event or
P. carinii pneumonia (Table 3). However, the proportion of patients who discontinued the study drug
either at their own request or because of intolerance
did not differ significantly between the atovaquone
and dapsone groups (relative risk, 1.21; P=0.05). The
risk of discontinuation for either of these reasons

Cumulative PercentageI
of Patients

*Relative risks (RR) for atovaquone versus dapsone and associated P values and 95 percent confidence intervals (CI) are derived from a Cox proportionalhazards regression model with stratification factors corresponding to research organization (CPCRA or ACTG), presence or absence of a history of P. carinii
pneumonia, and toxoplasmosis titer at base line. Rates are per 100 person-years. For comparisons with no events in one treatment group, P values were
calculated with Fisher’s exact test.

100
90
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Figure 2. Kaplan–Meier Estimates of the Percentage of Patients
Who Continued to Take the Assigned Study Drug without the
Development of Intolerance.
Blue lines represent patients receiving dapsone at base line,
red lines patients not receiving dapsone at base line, solid lines
patients assigned to atovaquone, and dashed lines patients assigned to dapsone.

was significantly influenced by base-line use of dapsone (Table 3).
The median time during which patients received
the study medication was similar in the two treatment
groups but differed significantly according to dapsone
use at base line (Fig. 2). The median time that patients
continued to use assigned dapsone was 10.9 months
for those who were receiving dapsone at base line and
3.9 months for those who were not (P<0.001). The
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median time that patients continued to use atovaquone was similar in these two subgroups: 7.0 months
for those who were receiving dapsone at base line and
7.4 months for those who were not.
DISCUSSION

In patients with HIV infection, the use of trimethoprim–sulfamethoxazole as prophylactic treatment
has been limited by adverse events.6,7 Various regimens
for desensitization to trimethoprim–sulfamethoxazole
have been recommended,11 and dose escalation has
been attempted.12,13 These strategies may be inadvisable or unsuccessful in some patients, necessitating
the use of alternative agents, including dapsone,
dapsone plus pyrimethamine, and aerosolized pentamidine.14 In this study, atovaquone suspension and
dapsone at a 100-mg daily dose were similarly effective
for the prevention of P. carinii pneumonia among
patients who could not tolerate trimethoprim–sulfamethoxazole. This finding was consistent for both
patients who were receiving primary prophylaxis and
those who were receiving secondary prophylaxis and
for both patients who were receiving dapsone at
base line and those who were not.
The efficacy of dapsone as prophylaxis against
P. carinii pneumonia has been evaluated in several
studies that used various doses of dapsone, with or
without pyrimethamine.6,7 With the exception of
one small study, none of these studies were specifically designed to enroll patients who could not tolerate trimethoprim–sulfamethoxazole.15
A potential advantage of atovaquone for the prevention of P. carinii pneumonia is its antitoxoplasma
activity.14 Although we found that atovaquone and
dapsone had similar efficacy for the prevention of
P. carinii pneumonia, we were unable to evaluate
the efficacy of atovaquone for the prevention of toxoplasmosis because of the low seroprevalence of toxoplasma among the study participants and the occurrence of very few cases of toxoplasmosis.
The rates of P. carinii pneumonia decreased with
increasing duration of follow-up in both treatment
groups, perhaps as a result of the introduction of more
potent antiretroviral therapies during the course of
the study. (Seventy-two percent of the participants
at two years of follow-up were receiving regimens
containing protease inhibitors.) There was also a substantial decline in the rates of HIV-related opportunistic events during this time.16,17 On the other
hand, it is not clear why there was a greater decline
in the rate of P. carinii pneumonia among the patients who discontinued the study medications than
among those who continued to receive them. The
regimens used as prophylaxis against P. carinii pneumonia (largely aerosolized pentamidine and dapsone)
by patients who discontinued the assigned treatment
are unlikely to explain the lower rate of P. carinii
pneumonia. It is also unlikely that patients who dis1894 ·

continued the study medications were those with a
more favorable response to antiretroviral therapy and
a lower risk of P. carinii pneumonia. It is possible
that those who discontinued treatment and became
lost to follow-up (about 6 percent of the patients)
had a higher rate of P. carinii pneumonia. The similar rate of loss to follow-up in the two treatment
groups reduces the likelihood of a bias in the treatment effects.
A substantial proportion of participants had adverse events that necessitated discontinuation of the
study drugs. Overall, there was no significant difference between the atovaquone and dapsone groups
in the rate of adverse events or in the median time
during which patients received the assigned treatment. However, dapsone use before randomization
was an important determinant of the relative tolerance of these two regimens. Patients who were receiving dapsone at base line were randomly assigned
to either the continued use of dapsone or the initiation of atovaquone. Because few patients were receiving atovaquone before randomization, a comparable group of patients receiving atovaquone at base
line could not be studied. Patients who were receiving dapsone at base line were more likely to tolerate
the continued use of dapsone than the initiation of
atovaquone. The opposite was true for those not receiving dapsone at base line: they tolerated atovaquone better than dapsone. The results for the patients in the latter group, who did not already have
a demonstrated tolerance of dapsone, may be more
applicable to patients who cannot tolerate trimethoprim–sulfamethoxazole and who are therefore newly
eligible for alternative prophylactic regimens.
Each treatment was associated with distinct patterns of adverse events. With atovaquone, there were
significantly higher rates of upper gastrointestinal
symptoms and diarrhea among the patients who were
receiving dapsone at base line. With dapsone, hypersensitivity reactions and anemia predominated.
Survival rates were similar whether patients were
assigned to atovaquone or to dapsone. A previous
study reported higher mortality among patients receiving dapsone than among those receiving aerosolized pentamidine for secondary prophylaxis against
P. carinii pneumonia.18 However, this result was not
confirmed in our study or in a recent meta-analysis.19
In conclusion, this large randomized study compared atovaquone with the most widely used alternative, dapsone, as prophylaxis against P. carinii pneumonia in HIV-infected patients with a history of
intolerance of trimethoprim–sulfamethoxazole. The
rates of P. carinii pneumonia, survival, and tolerance
were similar in the atovaquone and dapsone groups.
However, among patients who were not receiving
dapsone at base line, atovaquone was better tolerated,
and it may be the preferred therapy for such patients. Patients who were already receiving dapsone
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tolerated it better than atovaquone, a result indicating that such patients should continue to take dapsone. The high rates of P. carinii pneumonia and intolerance with both medications suggest that further
research is needed to find better options for prophylaxis against P. carinii pneumonia among patients who
cannot tolerate trimethoprim–sulfamethoxazole.
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Francisco: J. Pannell, C. Brosgart, and F. Strauss; Harlem AIDS Treatment
Group, New York: J. Wennberg, S. Caras, and C. Guity; Henry Ford Hospital, Detroit: L. Faber, L. Makohon, and D. Mastro-Polak; Louisiana
Community AIDS Program, New Orleans: C.L. Besch, Sr., S. Pablovich,
and S. Leblanc; North Jersey Community Research Initiative, Newark,
N.J.: C. Forrester, N. Regevik, and R. Nahass; Richmond AIDS Consortium,
Richmond, Va.: T.M. Kerkering, C. Webster, and J. Brooks; Research and
Education Group, Portland, Oreg.: R. Lusk, C. Salveson, and J.H. Sampson; Washington Regional AIDS Program, Washington, D.C.: F. Nunley,
K. Shade, and B. Staton; Wayne State University, Detroit: L. Crane, R.
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Beth Israel Deaconess Medical Center, Boston: H. Heller; Howard University, Washington, D.C.: R. Delapenha, J. McNeil, and Y. Butler; Indiana
University Hospital, Indianapolis: J. Black, S. Ryan, and H. Nixon; Johns
Hopkins University, Baltimore: M. Higgins, P. Brooks, and J. Feinberg;
Mount Sinai Medical Center, New York: D. Mildvan, B. Simpson, and V.
Koslowski; New York University, New York: V. Rosenwald and R. Gulick;
Northwestern University, Evanston, Ill.: P. Donath, N. French, and B. Sha;
Ohio State University, Columbus: R.J. Fass, C.O. Mills, and J.L. Neidig;
Stanford University, Palo Alto, Calif.: T.C. Merigan, Jr., D. Israelski, and
D. Slamowitz; University of Alabama at Birmingham: L. Alldredge, S.
Wells, and K.E. Squires; UCLA School of Medicine: G. Mathisen and G.
Beall; Harbor–UCLA Medical Center: M. Guerrero; University of California, San Diego: R. Haubrich, R. Snyder, and D. Richman; University of
California, San Francisco: E. San Juan, H. Woodring, and D. Gary; University of Cincinnati, Cincinnati: M. Dohn, J. Black, and J. Sanchez; University of Colorado Health Sciences Center, Denver: G. Ray, B. Putnam,
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D.T. Jayaweera, J. Cole, and L. Thompson; University of Minnesota, Minneapolis: J.T. Stapleton, S. Swindells, and C. Kumekawa; University of
North Carolina, Chapel Hill: D. Ragan and B. Longmire; University of
Pennsylvania, Philadelphia: S. Hauptman, R.R. MacGregor, and E. Donaghy; University of Rochester Medical Center, Rochester, N.Y.: R. Reichman, R. Hewitt, and D. Blair; University of Southern California, Los Angeles: M.P. Dube, V.T. Clemente, and J.M. Leedom; University of Texas,
Galveston: R.B. Pollard, M.J. Borucki, and A. Caballero; University of

Washington, Seattle: B.A. Royer, J. Lund, and A.C. Collier; Vanderbilt
University, Nashville: M.A. South, S. Raffanti, and D. Haas; Washington
University, St. Louis: W.G. Powderly, C.J. Fichtenbaum, and G. Hamilton;
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